Nicotinamide phosphoribosyltransferase mRNA (NAMPT mRNA)

Nicotinamide phosphoribosyltransferase (NAMPT) mRNA is the primary transcript encoding the NAMPT enzyme, which serves as the rate-limiting factor in the nicotinamide adenine dinucleotide (NAD+) salvage pathway [1]. This pathway is essential for maintaining cellular NAD+ levels, which are critical for energy metabolism, DNA repair, and the activity of NAD+-dependent enzymes like sirtuins and PARPs [2]. In many pathological states, particularly in aggressive cancers, NAMPT mRNA is overexpressed to support the high metabolic demands and survival of malignant cells [3]. Targeting NAMPT at the mRNA level using RNA interference (RNAi) or antisense oligonucleotides (ASOs) represents a therapeutic strategy to deplete the intracellular NAD+ pool, thereby inducing metabolic stress and cell death [4]. Beyond its intracellular role, the protein encoded by this mRNA also functions extracellularly as a pro-inflammatory cytokine known as visfatin, linking it to inflammatory and metabolic disorders such as obesity and type 2 diabetes [5]. While protein-level inhibitors have been extensively studied, mRNA-targeted approaches offer a way to achieve high specificity and potentially overcome some of the resistance mechanisms associated with small molecule inhibitors [6]. However, therapeutic development faces challenges including the risk of systemic NAD+ depletion in healthy tissues and the requirement for sophisticated delivery systems to ensure effective uptake in target cells [7].

Other names

PBEF1 mRNAVisfatin mRNAPre-B-cell colony-enhancing factor 1 mRNA

RNA interference (RNAi) or antisense-mediated degradation leading to the reduction of NAMPT protein synthesis and subsequent depletion of intracellular NAD+ pools.